| Project/Area Number |
16K19464
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Respiratory organ internal medicine
|
|---|
| Research Institution | Wakayama Medical University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2016-04-01 – 2018-03-31
|
| Project Status |
Completed (Fiscal Year 2017)
|
| Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2017: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2016: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
|---|
| Keywords | 肺癌 / リキッドバイオプシー / immunotherapy / lung cancer / Liquid biopsy / 血中循環腫瘍細胞 / cell free DNA / 臨床呼吸器学 |
|---|
| Outline of Final Research Achievements |
Blood samples were collected from 76 patients who receive immune-checkpoint inhibitors. We did comprehensive somatic mutation analysis using extracted cell-free DNA by next generation sequencing. Addition to that, circulating tumor cells (CTCs) were analyzed for PD-L1 expression by immunohistochemical staining (22c3 antibody). First analysis was done in the first 29 patients. CTCs were detected in all patients, and median number of CTCs were 15 / 5mL (range 1 to 90 / 5mL). Regarding PD-L1 expression, no correlation was observed between CTCs and tumor tissue. Significantly higher disease control rate was observed when >50% of CTCs were positive for PD-L1.
These outcomes described above were reported in American Society of Clinical Oncology 2017, and we are preparing manuscript.
|
